Navigation Links
Celsion Announces CFO Departure
Date:1/8/2010

COLUMBIA, Md., Jan. 8 /PRNewswire-FirstCall/ -- CELSION CORPORATION (Nasdaq: CLSN) today announced the departure of Sean F. Moran, Chief Financial Officer, effective January 8, 2010. Mr. Moran leaves Celsion to pursue other professional opportunities. Timothy J. Tumminello, CPA, the Company's controller, will assume the position of Interim Chief Accounting Officer and the responsibilities of the Company's financial officer. Celsion has retained CTPartners to lead its search for a new CFO.

"Celsion has great respect for Sean's work and expertise," commented Michael H. Tardugno, Celsion's President and CEO. "We wish him well in his future endeavors."

About Celsion

Celsion is dedicated to the development and commercialization of innovative oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated drug delivery systems. Celsion has licensed ThermoDox® to Yakult-Honsha for the Japanese market and has a partnership agreement with Phillips Medical to jointly develop its heat activated liposomal technology in combination with high intensity focused ultrasound to treat difficult cancers. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and the North Shore Long Island Jewish Health System.

For more information on Celsion, visit our website: http://www.celsion.com

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.


    Contact:
    Marcy Nanus
    The Trout Group, LLC
    646-378-2927
    mnanus@troutgroup.com

SOURCE Celsion Corporation

RELATED LINKS
http://www.celsion.com

'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
2. Warner Chilcott Announces Early Tender Results and Receipt of Consents from a Majority of Holders of its 8-3/4% Senior Subordinated Notes due 2015
3. Vion Pharmaceuticals Announces FDA Conclusion
4. Connectyx Announces MedFlash Sales Partnership with National Recreational Vehicle Club
5. Arigene Co., Ltd. Announces Termination of Tender Offer To Purchase and Return of Validly Tendered Shares of Common Stock of Trimeris, Inc.
6. Vermillion Announces $43.05 Million Private Placement of Common Stock
7. ViVre Medical Announces $6,000,000 Gift
8. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
9. Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer
10. Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
11. Raptor Pharmaceutical Corp. Announces Closing of $7.5 Million Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... FRANCISCO , April 27, 2016 ... expected to reach USD 2.06 billion by 2022, ... Research, Inc. Increasing consumer awareness towards a healthy ... the next seven years.      (Logo: ... diet intake coupled with rising health treatment expenditure ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online plastic surgery community, ... forum section was recently revamped and upgraded to allow even more interaction between doctors ... the country. , According to the senior editor of Cosmetic Town, “We are excited ...
(Date:4/28/2016)... ... April 28, 2016 , ... Horizon ... collaborating with doctors and hospitals to make transformative changes in how health care ... therapy minds this week in discussing breakthroughs in cellular medicine to treat disease. ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... USA Medical Card reminds us that May ... (CDC), a stroke is the fourth leading cause of death in the United States; someone ... almost a quarter of them in individuals under 65 years old. A stroke is ...
(Date:4/28/2016)... PA (PRWEB) , ... April 28, 2016 , ... ... Browne, M.D. has been named a Top Doc in Physical Medicine and Rehabilitation ... conjunction with Castle Connolly Medical, Ltd. by randomly surveying physicians and medical leadership ...
(Date:4/28/2016)... ... April 28, 2016 , ... Denise McCormick Baich had written poetry dating back to her ... again much like a tsunami and took on a more spiritual tone. The desire to ... to do more with it than just file it away. Friends would ask her how ...
Breaking Medicine News(10 mins):